Ginkgo Bioworks Holdings (DNA) Cash from Operations Growth (1y) (2021 - 2026)
Ginkgo Bioworks Holdings (DNA) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 158.60% |
| 10 | Ginkgo Bioworks Holdings | 441.96 Mn | 298.10 Mn | 16.38 Mn | -8.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.62% |
| Dec 31, 2025 | -12.36% |
| Sep 30, 2025 | 69.46% |
| Jun 30, 2025 | 41.91% |
| Mar 31, 2025 | 52.11% |
| Dec 31, 2024 | 26.62% |
| Sep 30, 2024 | -40.72% |
| Jun 30, 2024 | -14.76% |
| Mar 31, 2024 | 1.46% |
| Dec 31, 2023 | 44.68% |
| Sep 30, 2023 | -159.34% |
| Jun 30, 2023 | 26.03% |
| Mar 31, 2023 | -355.25% |
| Dec 31, 2022 | 36.85% |
| Sep 30, 2022 | -441.76% |
| Jun 30, 2022 | -184.75% |
| Mar 31, 2022 | 58.66% |
| Dec 31, 2021 | -178.98% |